
A paper in The New England Journal of Medicine, Cell-free DNA Analysis for Noninvasive Examination of Trisomy, reports on the effectiveness of a new proprietary method to screen for Trisomy 21, which is the cause of 90% of cases where individuals exhibit Down Syndrome. This issue is well known at this point. There are many methods to screen and diagnose Down Syndrome prenatally, but they all suffer from drawbacks, from invasiveness to false positives. Currently the vogue is for methods which analyze maternal plasma. That is, all that’s needed is a blood draw from the mother. This is one such method.

But, I put a question mark in the title of this post because there is often an assumption that widespread screening will result in a massive decline in the number of individuals with Down Syndrome, to the point of extinction. Actually, I’m not sure about that. It seems that widespread adoption increases the pool of people who are getting tested, and fewer of these in the United States terminate pregnancies through abortion that the early adopters. As mean maternal age creeps up the number of people with Down Syndrome in the United States may not decrease nearly as much as we expect.

Comments are closed.